1
|
Abstract
Patients with myeloproliferative neoplasms (MPNs), a group of rare haematological conditions including polycythaemia vera, essential thrombocythaemia, and myelofibrosis, often experience a range of symptoms which can significantly impact their quality of life (QoL). Although symptom burden is highest in myelofibrosis and high-risk patients, lower-risk patients also report symptoms impacting their daily life and ability to work. In addition to physical symptoms, MPNs affect emotional well-being, with anxiety and depression frequently reported by patients. Despite significant advances in treatment options, such as the introduction of JAK1/JAK2 inhibitors, therapy for MPNs is often palliative; therefore, reduction of symptoms and improvement of QoL should be considered as major treatment goals. One of the main issues impacting MPN treatment is the discord between patient and physician perceptions of symptom burden, treatment goals, and expectations. New technologies, such as app-based reporting, can aid this communication, but are still not widely implemented. Additionally, regional variation further affects the psychosocial burden of MPNs on patients and their associates, as treatments and access to clinical trials are options for patients living in some areas, but not others. Overcoming some of the challenges in patient-physician communication and treatment access are key to improving disease management and QoL, as well as giving the patient greater input in treatment decisions.
Collapse
Affiliation(s)
- Cheryl Petruk
- Canadian MPN Research Foundation, Edmonton, AB, Canada.
| | | |
Collapse
|
2
|
Loscocco GG, Mannelli F, Guglielmelli P, Paoli C, Marone I, Cucci R, Coltro G, Sordi B, Albano F, Breccia M, De Stefano V, Finazzi G, Iurlo A, Martino B, Palandri F, Passamonti F, Siragusa S, Mannelli L, Fantoni D, Fazi P, Amadori S, Vignetti M, Barbui T, Vannucchi AM. Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. Am J Hematol 2019; 94:E239-E242. [PMID: 31179561 DOI: 10.1002/ajh.25555] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2019] [Accepted: 06/06/2019] [Indexed: 11/10/2022]
Affiliation(s)
- Giuseppe G. Loscocco
- CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, AOU Careggi, Dipartimento diMedicina Sperimentale Clinica, Università degli Studi Florence Italy
| | - Francesco Mannelli
- CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, AOU Careggi, Dipartimento diMedicina Sperimentale Clinica, Università degli Studi Florence Italy
| | - Paola Guglielmelli
- CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, AOU Careggi, Dipartimento diMedicina Sperimentale Clinica, Università degli Studi Florence Italy
| | - Chiara Paoli
- CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, AOU Careggi, Dipartimento diMedicina Sperimentale Clinica, Università degli Studi Florence Italy
| | - Ilaria Marone
- CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, AOU Careggi, Dipartimento diMedicina Sperimentale Clinica, Università degli Studi Florence Italy
| | | | - Giacomo Coltro
- CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, AOU Careggi, Dipartimento diMedicina Sperimentale Clinica, Università degli Studi Florence Italy
| | - Benedetta Sordi
- CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, AOU Careggi, Dipartimento diMedicina Sperimentale Clinica, Università degli Studi Florence Italy
| | - Francesco Albano
- Department of Emergency and Organ Transplantation (D.E.T.O.)Hematology Section, University of Bari Bari Italy
| | - Massimo Breccia
- Department of Hematology, Department of Translational and Precision MedicineSapienza University Rome Italy
| | - Valerio De Stefano
- Istituto di Ematologia, Università Cattolica Rome Italy
- IRCCSFondazione Policlinico Gemelli Rome Italy
| | - Guido Finazzi
- UOC Ematologia, ASST Papa Giovanni XXIII Bergamo Italy
| | - Alessandra Iurlo
- Hematology DivisionFoundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
| | - Bruno Martino
- Hematology UnitAzienda Ospedaliera “Bianchi‐Melacrino‐Morelli” Reggio Calabria Italy
| | - Francesca Palandri
- Institute of Hematology “L. and A. Seràgnoli”, St. Orsola‐Malpighi University Hospital Bologna Italy
| | - Francesco Passamonti
- Hematology UnitOspedale di Circolo ‐ ASST Sette Laghi, Università degli Studi dell'Insubria Varese Italy
| | - Sergio Siragusa
- Department of Health Promotion Sciences Maternal and Infantile CareInternal Medicine and Medical Specialities, University of Palermo Italy
| | - Lara Mannelli
- CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, AOU Careggi, Dipartimento diMedicina Sperimentale Clinica, Università degli Studi Florence Italy
| | - Duccio Fantoni
- CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, AOU Careggi, Dipartimento diMedicina Sperimentale Clinica, Università degli Studi Florence Italy
| | | | | | | | - Tiziano Barbui
- Foundation for Clinical Research (FROM), Papa Giovanni XXIIII Hospital Bergamo Italy
| | - Alessandro M. Vannucchi
- CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, AOU Careggi, Dipartimento diMedicina Sperimentale Clinica, Università degli Studi Florence Italy
| |
Collapse
|